Detalhe da pesquisa
1.
Covalent Binding Mechanism of Furmonertinib and Osimertinib With Human Serum Albumin.
Drug Metab Dispos
; 51(1): 8-16, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36328480
2.
Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans.
Xenobiotica
; 53(2): 69-83, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36745485
3.
Absorption, Distribution, Metabolism, and Excretion of [14C]BS1801, a Selenium-Containing Drug Candidate, in Rats.
Molecules
; 28(24)2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38138590
4.
Mechanistic Study on the Species Differences in Excretion Pathway of HR011303 in Humans and Rats.
Drug Metab Dispos
; 50(6): 809-818, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862251
5.
Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase.
Drug Metab Dispos
; 50(6): 798-808, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862252
6.
Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers.
Br J Clin Pharmacol
; 88(7): 3307-3320, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112382
7.
Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes.
Acta Pharmacol Sin
; 43(3): 747-756, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34035488
8.
Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans.
Acta Pharmacol Sin
; 43(2): 494-503, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33927359
9.
Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model.
Acta Pharmacol Sin
; 43(7): 1865-1874, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34789919
10.
Absorption, distribution, metabolism, and excretion of [14C]TPN729 after oral administration to rats.
Xenobiotica
; 52(1): 79-90, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35038952
11.
Absorption, metabolism, and excretion of [14C]YY-20394, a highly selective PI3K-Delta inhibitor in humans.
Xenobiotica
; 52(3): 254-264, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373704
12.
Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.
Antimicrob Agents Chemother
; 65(11): e0040921, 2021 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34398672
13.
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
Invest New Drugs
; 39(4): 1011-1018, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33506323
14.
Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor.
Acta Pharmacol Sin
; 42(3): 482-490, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32581257
15.
Sulfation predominates the pharmacokinetics, metabolism, and excretion of forsythin in humans: major enzymes and transporters identified.
Acta Pharmacol Sin
; 42(2): 311-322, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32860005
16.
Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans.
Acta Pharmacol Sin
; 42(9): 1535-1546, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33244163
17.
A validated HPLC-MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor.
J Sep Sci
; 44(21): 3959-3966, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34472219
18.
Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor.
Br J Clin Pharmacol
; 86(9): 1860-1874, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32267573
19.
Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer.
Acta Pharmacol Sin
; 41(10): 1366-1376, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32235864
20.
Technologies to improve the sensitivity of existing chromatographic methods used for bioanalytical studies.
Biomed Chromatogr
; 34(3): e4798, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31994210